JPRN-UMIN000006294
Completed
未知
Efficacy of Nilotinib in Patients with Chronic Myeloid Leukemia in chronic phase unachieved Complete Molecular Response - Efficacy of Nilotinib in Patients with CML unachieved CMR
ConditionsChronic myelogenous leukemia
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Chronic myelogenous leukemia
- Sponsor
- Hyogo College of Medicine
- Enrollment
- 35
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Patients suspected in AP and BC 2\) Pregnant and/or lactating woman 3\) Severe psychological disorders 4\) Uncontorlled complications
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Study of Nilotinib usefulness for chronic myeloid leukemia (CML) patients with Imatinib resistant or intolerant.Chronic myeloid leukemiaJPRN-UMIN000003016Osaka CML-MRD Meeting45
Active, not recruiting
Phase 1
Treatment for patients whith graft-versus-host disease after bone marrow transplantation.Chronic graft-versus-host disease .MedDRA version: 14.1Level: LLTClassification code 10008907Term: Chronic GVH diseaseSystem Organ Class: 100000004870Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-000770-36-BECHU-ULg5
Not yet recruiting
Not Applicable
To stop the use of Imatinib in CML-CP patientsCTRI/2019/07/020407DR BRA IRCH AIIMS
Completed
Phase 2
Effect of Imatinib Mesylate in patients undergone allogeneic bone marrow transplantation who show chronic coetaneous involvement Graft Versus-Host Disease.cutaneous cGVHD.Graft-versus-host reaction or diseaseIRCT201302261030N12Hematology-Oncology and SCT Research Center28
Completed
Phase 2
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.Philadelphia Positive (Ph+) Chronic Myelogenous LeukemiaNCT01844765Novartis Pharmaceuticals59